Cancer patients get continued access to promising drug

NCT ID NCT02934568

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enrolled, and they must be getting clinical benefit as judged by their doctor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ribociclib (LEE011)
What this could lead to: If successful, this study allows patients with advanced cancers to keep receiving a treatment that is already working for them, potentially extending their benefit.
What could go wrong: This is a small rollover study (22 patients) with no control group, so results may not apply broadly. Side effects like liver issues or serious adverse events are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTINUED ACCESS TO STUDY TREATMENT(S), CANCERS WITH A MASS, BULKY TUMOR, NODULE, LUMP, ADVANCED CANCER, ADVANCED SOLID TUMORS, ADVANCED SOLID MALIGNANCIES

Contacts and locations

Locations

Broome Oncology

Johnson City, New York, 13790, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site

Singapore, 119228, Singapore
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Madrid, 28050, Spain
Novartis Investigative Site

Tainan, 704302, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
St Jude Childrens Research Hospital

Memphis, Tennessee, 38105, United States
The Regents of the Uni of Michigan

Ann Arbor, Michigan, 48109-5930, United States
University Of Alabama At Birmingham

Birmingham, Alabama, 35294-3300, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.